[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tarsus Pharmaceuticals Inc (TARS)

Tarsus Pharmaceuticals Inc (TARS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,633,499
  • Shares Outstanding, K 43,024
  • Annual Sales, $ 451,360 K
  • Annual Income, $ -66,420 K
  • EBIT $ -71 M
  • EBITDA $ -74 M
  • 60-Month Beta 0.52
  • Price/Sales 6.10
  • Price/Cash Flow N/A
  • Price/Book 7.89

Options Overview Details

View History
  • Implied Volatility 53.61% (+0.99%)
  • Historical Volatility 38.82%
  • IV Percentile 34%
  • IV Rank 35.43%
  • IV High 82.12% on 04/17/26
  • IV Low 37.97% on 08/20/25
  • Expected Move (DTE 4) 6.50 (10.90%)
  • Put/Call Vol Ratio 0.63
  • Today's Volume 26
  • Volume Avg (30-Day) 654
  • Put/Call OI Ratio 2.32
  • Today's Open Interest 15,804
  • Open Int (30-Day) 11,114
  • Expected Range 53.15 to 66.15

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.22
  • Number of Estimates 5
  • High Estimate $-0.12
  • Low Estimate $-0.36
  • Prior Year $-0.48
  • Growth Rate Est. (year over year) +54.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
57.81 +3.19%
on 05/11/26
74.39 -19.81%
on 04/15/26
-12.91 (-17.79%)
since 04/10/26
3-Month
57.81 +3.19%
on 05/11/26
80.00 -25.44%
on 02/24/26
-5.74 (-8.78%)
since 02/11/26
52-Week
38.51 +54.89%
on 08/01/25
85.25 -30.03%
on 12/09/25
+14.89 (+33.27%)
since 05/09/25

Most Recent Stories

More News
Tarsus to Participate in Upcoming Investor Conferences

IRVINE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences: ...

TARS : 59.65 (-2.55%)
Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements

Generated first quarter XDEMVY ® net product sales of more than $145 million, an increase of more than 85% year-over-year Reaffirmed full-year 2026 guidance of $670-700 million of XDEMVY net...

TARS : 59.65 (-2.55%)
Can Tarsus Pharmaceuticals Justify Its Valuation Before the Launch Window Closes?

Barchart Research What to Expect from TARS Earnings TARS Generated May 5, 2026 Current Price $65.04 EPS Estimate $$-0.43 Consensus Rating Strong Buy Average Move 7.42% Can Tarsus Pharmaceuticals Justify...

TARS : 59.65 (-2.55%)
Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026

IRVINE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Wednesday, May 6, 2026...

TARS : 59.65 (-2.55%)
Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease

– A pioneering investigational oral prophylactic approach designed to kill  Lyme-infected ticks before disease transmission –   IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Tarsus...

TARS : 59.65 (-2.55%)
TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus

IRVINE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced that a $15 million milestone payment due Tarsus has been achieved following regulatory approval...

TARS : 59.65 (-2.55%)
Tarsus to Participate in Upcoming Investor Conferences

IRVINE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences: ...

TARS : 59.65 (-2.55%)
Tarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Achievements

Generated full-year 2025 net product sales of XDEMVY ® of $451.4 million , an increase of more than 150% year-over-year Providing expected XDEMVY peak sales potential of more than $2 billion...

TARS : 59.65 (-2.55%)
Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors

IRVINE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced the appointment of David E. I. Pyott, a distinguished leader in the global biopharmaceutical...

TARS : 59.65 (-2.55%)
Tarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026

IRVINE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Monday, February 23,...

TARS : 59.65 (-2.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

Tarsus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapeutic candidates to address ophthalmic conditions. The company's product candidate consist TP-03 which is in clinical stage. Tarsus Pharmaceuticals Inc. is based...

See More

Key Turning Points

3rd Resistance Point 65.23
2nd Resistance Point 63.38
1st Resistance Point 61.51
Last Price 59.65
1st Support Level 57.80
2nd Support Level 55.94
3rd Support Level 54.08

See More

52-Week High 85.25
Fibonacci 61.8% 67.40
Fibonacci 50% 61.88
Last Price 59.65
Fibonacci 38.2% 56.36
52-Week Low 38.51

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.